InSilico Medicine Cayman TopCo (FRA:O15) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo ROCE %?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InSilico Medicine Cayman TopCo's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

InSilico Medicine Cayman TopCo  (FRA:O15) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InSilico Medicine Cayman TopCo ROCE % Related Terms

InSilico Medicine Cayman TopCo ROCE % Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo ROCE % Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 0.00 0.00 0.00

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo ROCE % Calculation

InSilico Medicine Cayman TopCo's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-300.648/( ( (137.522 - 770.558) + (418.445 - 28.945) )/ 2 )
=-300.648/( (-633.036+389.5)/ 2 )
=-300.648/-121.768
=246.90 %

InSilico Medicine Cayman TopCo's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-568.712/( ( (209.217 - 795.825) + (418.445 - 28.945) )/ 2 )
=-568.712/( ( -586.608 + 389.5 )/ 2 )
=-568.712/-98.554
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a ROCE % of 0.00% as of Dec. 2025.
Is InSilico Medicine Cayman TopCo's ROCE % too high?
InSilico Medicine Cayman TopCo's current ROCE % is 0.00%. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's ROCE % compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's ROCE % of 0.00% can be compared against companies in the Software industry. The industry median ROCE % is 5.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Software company?
The median ROCE % among Software companies is 5.92, based on 2,722 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Software industry, the median ROCE % is 5.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price